Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Phase 3 trials of treatment combo for hepatitis D expected in 2025
Vir Biotechnology plans 2025 Phase 3 ECLIPSE program to test tobevibart and elebsiran for chronic hepatitis D, following positive Phase 2 SOLSTICE data showing viral suppression and liver marker normalization. The Phase 3 program includes two trials and a head-to-head study, aiming for regulatory approval and addressing treatment gaps.
Related Clinical Trials:
Vir Biotechnology's Promising Therapeutic Advancements Justify Buy Rating
Roanna Ruiz from Leerink Partners maintains a Buy rating on Vir Biotechnology (VIR) with a price target of $18.00, citing positive Phase 2 data for Hepatitis Delta Virus (HDV) and Hepatitis B Virus (HBV), and a promising regulatory path for HDV. Corporate insider sentiment on VIR is negative due to increased insider selling.
J.P. Morgan Sticks to Their Hold Rating for Vir Biotechnology (VIR)
J.P. Morgan's Eric Joseph maintains a Hold rating on Vir Biotechnology with a $10.00 price target. The analyst consensus is a Moderate Buy with an average price target of $29.71, indicating a 340.80% upside. Corporate insider sentiment is negative, with increased insider selling. Vir Biotechnology focuses on treating and preventing infectious diseases using antibody, T cell, innate immunity, and siRNA technologies.
Hold Rating Amidst Promising HDV Study Results and Future HBV Developments
Michael Ulz from Morgan Stanley maintains a Hold rating on Vir Biotechnology (VIR) with a $10.00 price target, citing consistent Phase 2 SOLSTICE study results in Hepatitis Delta Virus (HDV) but no significant breakthroughs. The ECLIPSE registration program and HBV functional cure data release in 2025 are anticipated, yet the current data does not alter the stock's risk-reward profile.
Vir Biotechnology's Promising Advancements in Hepatitis Treatments Justify Buy Rating
H.C. Wainwright's Patrick Trucchio reiterates Buy rating on Vir Biotechnology (VIR) due to promising Phase 2 data for viral hepatitis treatments, projecting peak revenue over $10 billion. The data supports combination therapies' efficacy, with significant rates of hepatitis B surface antigen loss and anti-HBs seroconversion in ongoing CHB program, indicating potential for functional cures.
Vir Biotechnology poised for outperformance, keeps buy rating on pipeline potential
TD Cowen maintains Buy rating on Vir Biotechnology, citing promising data for HBV and HDV treatments. Eleb+tobe combination therapy for HDV could start pivotal program in 2025. Vir's negative enterprise value presents potential for stock outperformance. Recent progress includes positive EMA opinions for orphan drug designations and a licensing agreement with Sanofi. Despite financial challenges, Vir's cash reserves and pipeline advancements suggest a bullish outlook.
Holding Pattern: Awaiting Clarity on Vir Biotechnology's Potential Amid Promising Trials
Alec Stranahan from Bank of America Securities maintains a Hold rating on Vir Biotechnology (VIR) with a $15.00 price target, citing cautious optimism due to promising SOLSTICE trial results and anticipation of ECLIPSE phase 3 trials in 2025 to clarify competitive positioning.
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data
Vir Biotechnology's SOLSTICE Phase 2 trial shows 100% virologic suppression with tobevibart and elebsiran combination at Week 24, sustained through Week 60, with 80% HDV RNA TND by Week 60. The combination is well-tolerated, with no severe AEs or discontinuations. Phase 3 ECLIPSE program to start in H1 2025.
Related Clinical Trials:
Promising Data and Strategic Developments Justify Buy Rating
Needham's Joseph Stringer maintains Buy rating on Vir Biotechnology (VIR) with $19.00 price target, citing promising Hepatitis B and D clinical data. Barclays also assigns a Buy rating with a $26.00 target.
Vir Biotechnology announces results from SOLSTICE trial
Vir Biotechnology's SOLSTICE Phase 2 trial showed 100% virologic response and rapid HDV RNA suppression with tobevibart and elebsiran combination for CHD, with 80% achieving HDV RNA TND by Week 60. The Phase 3 ECLIPSE program is planned for 2025 to further evaluate this combination.
© Copyright 2024. All Rights Reserved by MedPath